Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesna for reduction of lipid peroxidation during CABG surgery
IRCT20260110068598N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of mesna in coronary arteriosclerosis (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Reduction of inflammation due to surgery and Malondialdehyde measurement. Started Jan 2026; status: completed.
02
Drugs
mesna
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20260110068598N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260110068598N1.